Changing Medicine, Changing Lives

KKNA Introduction

November 2024

Global Vision

Our Vision toward 2030

Kyowa Kirin will realize the successful creation and delivery of life-changing value that ultimately makes people smile, as a Japan-based Global Specialty Pharmaceutical company built on the diverse team of experts with shared passion for innovation.

Provide pharmaceuticals for unmet medical needs

We are focused on developing medicines for diseases where there is a clear patient need for new options. We make full use of multiple therapeutic modalities, including biotechnology such as antibody technology, and beyond, building on our Kyowa Kirin established strengths.

Address patient-centric healthcare needs

We will meet the needs of patients and society by providing value across the entire patient care pathway, delivering cutting-edge science and technology, grounded in our in-depth pharmaceutical knowledge and expertise.

Retain the trust of society

We pursue world-class product quality and operational excellence to grow our business in ways which build long-term trust with our stakeholders.

Four core values drive all we do and who we are

Commitment to Life

Create new value for patients, caregivers, healthcare professionals, and society.

Innovation

Go beyond boundaries. Challenge the status quo in all our work.

Teamwork / Wa

Work in diverse and talented teams, united by respect and the desire to make a difference in people's lives.

Integrity

Do the right thing.
Be sincere and ethical.
Make a better world through good business practices.

Kyowa KIRIN North America

We are a Japan-based global specialty pharmaceutical company backed by more than 70 years of pioneering science and breakthrough innovation.

Our team is working to engineer the next generation of antibodies, cell and gene therapies with the potential to deliver life-changing value to patients living with underserved and rare diseases.

A shared commitment to our values, building relationships, and making people smile unites us, as one team.

We will take advantage of our size, focus, data and empathy to solve the problems that matter most to our patients. And in doing so, become the world's most admired and trusted rare disease company.

North America Pioneers New Capabilities to Support Global Growth

Across four locations in North America, we work from discovery to development to commercialization with the unifying goal of having a profound impact on the lives of patients, families, and communities.

Global Business

44 Global Markets

4 Regions Worldwide

4 Therapeutic Areas

50+ Pharmaceutical Products

21 Drugs in Clinical Development

5 Research Facilities

~6,000 Valuable Colleagues

Kyowa Kirin North America (KKNA)

4 Locations

1 Research Facility

20+ Patient Advocacy Group Connections

670 Valuable Colleagues

~31%

of Global Revenues Contributed by KKNA in FY 2023

Up from 13% in 2019 to $860M

KKNA revenue contribution to the global business is growing



In 2023, Kyowa Kirin North America accounted for 31% of the company's total global revenues – up from 13% in 2019.

Four locations

- Headquarters: Princeton, NJ
- Research: La Jolla, CA
- Offices: Mississauga, Ontario
- Manufacturing: Coming soon to North Carolina

Patient needs are at the heart of our business

We are distinguished by our long-standing commitment and relationships with patient organizations, which are grounded in a shared interest to help patients access better care and treatment options.

WORKING TOGETHER TO HAVE A PROFOUND IMPACT

PMD Alliance
Parkinson & Movement Disorder Alliance

Cutaneous Lymphoma Foundation

XLH Network

International Alliance of Dermatology Patient Organizations

NORD®

Lymphoma Canada

National Eczema Association

Canadian XLH Network

EveryLife Foundation for Rare Diseases

Global Parents for Eczema Research

Lymphoma Research Foundation

CORD Canadian Organization for Rare Disorders

Leukemia & Lymphoma Society

Rare Disease Company Coalition

Global Genes®
Allies in Rare Disease

Remember The Girls XXXXX

Kyowa Kirin

Kyowa Kirin North America Human Resources

Kyowa Kirin North America (KKNA)

Approx 670 Employees (as of 10/31/24)



Canada
15～people

Orchard therapeutics

Boston
30～people
(1Expat)

Field Sales/Remote
200～people

Princeton
300～people
(36 Expats)

Function	Expats
MA	1
RA	1
QA	1
PV	4
BD	2
Research	7
Development	13
Manufacturing	3
GPM	7
CP	1
Finance	1
HR	1
ICT	2
Grand Total	**44**

San Diego
50～people
(7 Expats)



North Carolina
20～people
(1 Expat)

Why Kyowa Kirin Chose NJ

New Jersey is home to over 3,000 pharmaceutical companies

Includes 14 of the top 20 largest pharmaceutical companies in the United States

New Jersey is ideally located between Philadelphia & New York City on the Interstate 95 corridor and Princeton is easily accessible via train

In New Jersey, 43.8% of the population has a bachelor's degree or higher which is significantly higher than the national rate of 33.7%

LinkedIn reports over 116,000 professionals work in the Pharmaceutical industry in New Jersey

LinkedIn reports gender balance in the industry in NJ 51% female and 49% male



Kyowa KIRIN

Our Recruitment Journey

- KKNA has hired over **100 new roles** for the past few years through our internal recruitment team almost exclusively
- Our average **time to hire is below (faster than) industry average** at 46 days
- The acceptance rate on offers is at 92% for full-time employment which is **above industry average**
- **Reduced turnover** from above 20% 4 years ago to 10% last year which is below Industry average
- The expansion of our office in Princeton has been very successful in our talent workforce strategy coupled with our hybrid work policy

Kyowa KIRIN

Being a Japanese expat and living in New Jersey

Rieko Waxman

Corporate Planning Head

Kyowa Kirin, Inc.

駐在が決まった時の気持ち

- アメリカ（プリンストン）で生活することに対する不安
  - 安全性
  - 気候
  - 子供の教育ー現地の学校（就学前、公立学校）、日本語学校
  - 食事

- アメリカでの生活に対する期待
  - 日本ではできない経験

プリンストンでの２年半の生活

- 安全性
  - 全く問題なし。シカにだけ気を付けて。
- 気候
  - 冬は思ったよりもマイルド。室内は自動空調のため、日本よりも夏も冬も快適。ただし秋は朝と昼の温度の差は激しい。
- 子供の教育
  - 就学前のチャイルドケアの選択肢の多さ（カーネギーセンター内にも）
  - 全日制の公立キンダー
  - 現地学校での英語サポート、放課後教育
  - 日曜日本語学校と日本人コミュニティ
- 食事
  - 日本スーパーマーケット（雑貨、薬等も取り扱い）
  - 韓国系および中国系のスーパーマーケット
  - カフェ（本格抹茶カフェ、パンケーキ屋、寿司、韓国系ベーカリー等）



Princetonで楽しむ「アメリカならでは」

- 旅行（国内、国外）
  - Princeton Junctionからニューヨークまで１時間強、ワシントンDCまで３時間弱
  - ニューアーク空港まで車で１時間、トレントン空港まで２０分
  - ニュージャージーからのクルーズ乗船
- 住環境
  - アメニティの充実したアパートメント
  - ３階建てガレージ付きのタウンハウス
  - コミュニティのイベント（ハロウィーン、クリスマス等）
- その他
  - サマーキャンプ
  - ダイバーシティ
  - プリンストン大学（カレッジスポーツ、イベント、クラスの聴講）

Thank You.

COR-US-KKI-0091 April 2024

Carnegie Center

bxp

With significant presence in six markets and their surrounding sub-markets: Boston, New York, Los Angeles, San Francisco, Seattle and Washington, DC, BXP is the largest publicly traded developer, owner, and manager of premier workplaces in the United States. BXP's mission is to envision, develop, and man age exceptional properties that enhance client success, strengthen communities, and advance opportu nity. We create environments for forward-thinking companies to shape corporate culture, energize their wor kforce, and accelerate their growth.


Carnegie Center.
An inspiring and exceptional, creative
environment to work and collaborate.
Centrum Coffee

Strategically located at the exceptional focal point of the Route One Corridor in Princeton, mid-way between Philadelphia and New York City.

Princeton

Money Magazine's top 15 towns to live in America

A quality of life that is second to none

McCarter Theater
Photo by Matt Pilsner

Located at the “sweet spot” of commerce
in the Northeastern United States.
Conveniently accessible by rail, bus and air.



4 minutes to Princeton Junction Train Station
15 minutes to Trenton Mercer Airport
49 minutes to Newark Liberty International Airport
59 minutes to Philadelphia International Airport


Downtown Princeton
Dining in and Around Carnegie Center
There are more than 100 places to eat
within 4 miles of Carnegie Center
CARGOT
RUTH'S CHRIS STEAK HOUSE
SALT CREEK GRILLE
Scudders Mill Rd
Brunswick Rd
Washington Rd
Princeton Pike
Alexander Rd
Canal Pointe Blvd
Quaker Rd
Carnegie Center Dr
Meadow Rd
Market
Windsor
Nassau Park Pavilion
Mercer Mall
METRO North BAR·GRILL
PAPA JOHNS
SUBWAY
Shanghai Bun
Sultan Wok
Domino's
DUNKIN'
asianbistro
Allon's Pizza & Restaurant
The Bagel Hole
TERAKAWA RAMEN
Japanese Noodle House
ZAC'S BURGER
Pj's Pancake house
7 ELEVEN
Brick House Tavern + Tap
ON THE BORDER
corner bakery cafe
P.F. CHANG'S
QDOBA MEXICAN EATS
BOBBY'S BURGER PALACE
Bahama Breeze
FRIDAYS
Seasons 52
DUNKIN'
Princetonian DINER
ANJAPPAR
Jersey Mike's SUBS
roots
Panera BREAD
MASA SUSHI
Wendy's
Habit BURGER GRILL
SHAKE SHACK
ZOËS KITCHEN
TURNING POINT
Olive Garden
BONEFISH GRILL
KC prime
CHIPOTLE MEXICAN GRILL
BUFFALO WILD WINGS
MORE THAN Q BARBEQUE


Route 206
Downtown Princeton
Everything You Need is Nearby
amc THEATRES
BANANA REPUBLIC
GAP
WILLIAMS SONOMA
west elm
ANTHROPOLOGIE
POTTERY BARN
BARNES&NOBLE
LUKOIL
Staples
WHOLE FOODS MARKET
Wegmans
Michaels
MAKE CREATIVITY HAPPEN
TARGET
PETSMART
HomeGoods
DICK'S SPORTING GOODS
five BELOW
BEST BUY
Party City
THE HOME DEPOT
ShopRite
ROSS DRESS FOR LESS
BED BATH & BEYOND
REI
NORDSTROM rack
Princeton Pike
Quaker Rd
Nassau Park Pavilion
Mercer Mall
QUAKER BRIDGE MALL
Canal Pointe Blvd
Market
Alexander Rd
Carnegie Center Dr
Meadow Rd
TRADER JOE'S
LOWE'S
T.J.maxx
HOME SENSE
Walmart
FedEx Office
buy buy BABY
DOLLAR TREE
Brunswick Rd
SUNOCO
Washington Rd
Gulf
Scudders Mill Rd
Windsor
SUNOCO
Walgreens
RITE AID
VALERO

Hotels

Hospitality that’s uniquely Princeton

Talent and Academic Resources

Acclaimed and leading universities within an hour of Carnegie Center

Arguably, the best-trained workforce in the nation.

The Campus



A self-contained campus of magnificent buildings, punctuated with park-like expanses.

The Campus

The Campus


THE NERDS


Best Food
bon
Nut Butters & Sweets


Rita's
Rita's
Rita's

On Site Cafés

On Site Cafés

On Site Cafés

On Site Cafés

Fitness Center

Fitness Studios/Classes

Walking Paths

Bike Share


BIKE SHARE


BIKE SHARE
GRAB A BIKE & GO
bxp Boston Properties
Carnegie Center
bxp Boston Properties
Carnegie Center

Basketball/Volleyball

Bocce

Conference Centers

Childcare


Bright Horizons
Early Education & Preschool
609-419-0105
Bright Horizons

Helipad

Solar

Electric Charging



SCALE IN FEET

0 500

100 1000

T&M ASSOCIATES
CONSULTING ENGINEERS

YOUR GOALS. OUR MISSION.

CARNEGIE CENTER

PRINCETON, NEW JERSEY

bxp Boston Properties®

FEBRUARY, 2018

Kyowa Kirin	22K SF in 2001 – 80K SF Current
Taiho Oncology	13K SF in 2006 – 82K SF Current
Otsuka Pharmaceutical	22K SF in 2012 – 134K SF Current
Akros	15K SF in 2000 – 23K SF Current
Tsumura & Co.	1K SF in 2015 – 2,500 SF Current

The Integrated Development and Manufacturing Organization: The Future of Cell Therapy Manufacturing



Cellares is the World's first **Integrated Development & Manufacturing Organization (IDMO)**

CDMO → **10x productivity** → **IDMO**

Cellares can produce **10x** more cell therapy doses with the same facility size and the same headcount than conventional CDMOs

CELLARES

Vertical Integration

Advanced Technologies + Global Manufacturing Services

Cell Shuttle™

Compact automation enables concurrent processing of up to 16 batches and 90% reduction in labor and facility size

Cartridge

Closing and automating the process reduces process failure rates by 75% compared with open and manual methods

Software

Powerful and flexible software supports 90% of allogeneic and autologous cell therapy modalities

ADVANCED TECHNOLOGIES

MANUFACTURING SERVICES

South San Francisco (CA)

Preclinical & Clinical Services / Technology Development

- 57,000 ft²
- cGMP-ready in H1/2024
- 2 Cell Shuttles (capacity)
- 1,600 patient doses per year (based on a 7 day process)

Bridgewater (NJ)

Preclinical, Clinical & Commercial Services

- 118,000 ft²
- cGMP-ready in H2/2024
- 50 Cell Shuttles (capacity)
- 40,000 patient doses per year (based on a 7 day process)

CELLARES

The Cellares IDMO

Global Manufacturing Services Delivered via Integrated Technologies

Global Network of Smart Factories



- 10 Times as Many Cell Therapy Batches as Conventional CDMOs with the Same Facility Footprint and Headcount
- Automation and Integration Result in Up to 50% Reduction in Batch Prices Compared to Conventional CDMOs
- Rapidly Expand Into New Global Markets via Software-Driven Tech Transfer

Fully Integrated &Automated Technology

Cell Shuttle™ (Manufacturing)

Closes, Automates and Parallelizes All Cell Therapy Manufacturing Unit Operations

Cell Q™ (QC)

Fully Automates Cell Therapy Quality Control with the Ability to Automate In-Process & Batch Release QC

IDMO Software Suite (Integration)

Fully Integrated Software Stack Provides Closed-Loop Manufacturing and Full Traceability Vein-to-Vein

CELLARES

Cellares Invented Integrated Technologies For Automated, High Throughput CT Manufacturing and QC

ENRICHMENT ▸ SELECTION ▸ ACTIVATION ▸ TRANSFECTION ▸ TRANSDUCTION ▸ EXPANSION ▸ FORMULATION ▸ QC 1 ▸ QC 2 ▸ QC 3 ... QC 15

THE CELL SHUTTLE AUTOMATES MANUFACTURING

- 16 batches processed in parallel
- Majority of modalities supported

THE CELL Q AUTOMATES QC



- Throughput = 6,000 batches / year
- Reduced assay turnaround time

Cellares can produce 10x more cell therapy doses with the same facility size and the same headcount than conventional CDMOs

- 90% less labor required
- 90% less facility space required
- Reduced process failures

Cell Shuttle: Integrated Automated cGMP Manufacturing

CELLARES CELL SHUTTLE

Integrated cGMP Cell Therapy Manufacturing

The Cell Shuttle has achieved clinically relevant in-process & release specifications and cell doses as compared to commercial drug products

CD3+ T Cell Purity	Cell Viability	Transduction Frequency
>99%	**>95%**	**>65%**

Brochure: End-to-End Cell Therapy Manufacturing on the Cellares Cell Shuttle Platform

True Walk-Away End-to-End Manufacturing Automation from Loading the Starting Material to a Cell Therapy Drug Product

Single-Use Consumables Provide a **Closed & Automated End-to-End** Solution

cGMP Factory-in-a-box



Cellares Single-Use Cartridge Integrates All Unit Operations

- **Automation** eliminates opportunities for **operator error.**
- **Closing the process** eliminates opportunities for **contamination.**

Automated reagent bottles

Cellares Single-Use Reagents & Samples

- Reagent additions
- Sampling
- Waste removal

Software-Defined Manufacturing Enables Mass Customization

Software unlocks the full versatility of the hardware



- All processes use the same cartridge
- Majority of cell therapy modalities supported

Modular fluidic architecture enables flexibility to customize unit operations for different processes



Manufacturing processes in the cartridge are defined in software

CELLARES

Enabling Commercial Scale Manufacturing of Cell Therapies

\+

=



INTEGRATED AUTOMATION

All unit operations automated and enclosed in one Consumable Cartridge

HIGH-THROUGHPUT

Up to 16 cartridges for multi-product, concurrent manufacturing

SCALABILITY

Up to 2,800 batches per Cell Shuttle per year

Cell Q: Automated QC

CELLARES

CELLARES CELL Q

Integrated cGMP Cell Therapy QC

- Integrates and Automates Best-in-Class Industry-Standard QC Instrumentation
- Modular Design Provides Automates QC Assays and can incorporate future Assays
- A single Cell Q Supports the throughput of a Fleet of Cell Shuttles
- Automation Reduces the QC Labor Required and Assay Turnaround Time

Commercial-Scale Cell Therapy Manufacturing Requires the Automation of Release Testing (QC)

Automated High-Throughput Manufacturing

Cell Shuttles

Samples transferred via SLTDs or cryovials

Automated High-Throughput QC

Cell Q

- Automates majority of in-process and release QC assays
- 6,000 batches tested / yr
- Integrates & automates best-in-class, off-the-shelf QC instrumentation
- Technology enables Cellares IDMO to offer up to 50% lower batch price compared with conventional CDMO



Integrated Software Driven Automated Manufacturing

CELLARES

Integrated Software Stack

Complete Traceability = Closed Loop Vein-to-Vein





Automated Barcoding of Starting Materials and Reagents

Strict CoC & CoI



Software-Defined Manufacturing

Digitized Manufacturing Process

Flexibility + Rapid Tech Transfers

CELLARES

Cellares Overcomes the Limitations of Conventional CDMOs through the IDMO Advantage

Scale

Cost Savings

Speed

NJ Life Science Overview

November 2024

JLL SEE A BRIGHTER WAY

Talent concentration

Talent concentration with NJ based LS and Consumer Product companies

Life science & consumer product companies

- Beckton Dickinson
- Glenmark
- Psycho Genesis
- Eisai
- Cambrex
- Modern Meadow
- Teva
- Ferring Pharmaceuticals
- DSM
- Pacira
- Zoetis
- Gilead
- Alovgen
- Bayer
- Shinogi
- Cellularity
- Pfizer
- Abbvie
- Merck
- Leo Pharma
- Lonza
- Hikma
- Bristol Myers Squibb
- Helsinn
- Actavis
- Mitsubishi Tanabe Pharma
- Organon
- Biolabs NYU Langone
- Mispro
- Lilly
- Pfizer
- Kadmon
- NYU Langone Health
- Amneal
- Pfizer
- Daiichi-Sankyo
- Ipsen
- Aurobindo
- GSK
- Sanofi
- Ethicon
- Amarin Corporation
- Jansen
- Johnson & Johnson
- Ortho Clinical Diagnostics
- Roche
- Lilly
- Advaxis
- Sandoz
- Firmenich
- Novo Nordisk
- WuXi
- Bioclinica
- Otsuka
- Akros Pharma
- Aurobindo
- BMS
- Prevail
- Cellectis
- Alexandria Launch Labs
- Astra Zeneca
- Mallinckrodt
- Janssen



Northeast Corridor Rail Line



Lab demand driver #1: Funding

More than $353 million of VC funding poured into New Jersey's life sciences industry during 1H 2024, with nearly 50% of capital raised in the Series A stage



Source: Crunchbase

Lab demand driver #1: Funding

Nearly $500 million of VC funding was invested in Philadelphia's life sciences industry during 1H 2024, with nearly 3/4 of capital raised in the Series A stage



Source: Crunchbase

Lab demand driver #1: Funding

More than $2.5 billion of VC funding poured into the NYC's sciences industry during 1H 2024, which rivaled the $2.1 billion in funding raised during all of 2023



Source: Crunchbase

New Jersey clinical trial production boom

Drug pipeline points to a wave of demand for clinical trial production progressing from Phase III to FDA drug review

Stage	Drugs in pipeline: NJ	% of U.S. pipeline	Overall success	Projected successful drugs to market
Phase 1	62	7%	13.8%	9
Phase 2	119	9%	21.0%	25
Phase 3	163	29%	59.0%	96
Total	**344**	**12%**	**13.8%**	**47**



Source: Global Data; MIT

- New Jersey is responsible for 12% of drugs in the U.S. pipeline.
- Nearly 50% of therapies in the Garden State's drug development pipeline were in the Phase III stage at year-end 2023.
- Artificial intelligence (AI) methods are now critical in the R&D process and throughout the drug development pipeline. Implementation of AI technology can accelerate productivity in drug discovery, clinical trials, testing of existing drugs for new uses and aggregation of data at scale.
- Established biopharma companies are increasingly investing in AI-focused start-ups, and this field will continue to be a primary driver of the life sciences innovation engine.

Philadelphia clinical trial production boom

Drug pipeline points to a wave of demand for clinical trial production progressing from Phase III to FDA drug review

Stage	Drugs in pipeline: Phila.	% of U.S. pipeline	Overall success	Projected successful drugs to market
Phase 1	0	0%	13.8%	0
Phase 2	2	0%	21.0%	0
Phase 3	8	1%	59.0%	5
Total	**10**	**0%**	**13.8%**	**1**



Source: Global Data, MIT

- Approximately 80% of therapies in the Philadelphia drug development pipeline were in the Phase III stage at year-end 2023.
- Artificial intelligence (AI) methods are now critical in the R&D process and throughout the drug development pipeline. Implementation of AI technology can accelerate productivity in drug discovery, clinical trials, testing of existing drugs for new uses and aggregation of data at scale.
- Established biopharma companies are increasingly investing in AI-focused start-ups, and this field will continue to be a primary driver of the life sciences innovation engine.

NYC clinical trial production boom

Drug pipeline points to a wave of demand for clinical trial production progressing from Phase III to FDA drug review

Stage	Drugs in pipeline: NYC	% of U.S. pipeline	Overall success	Projected successful drugs to market
Phase 1	3	0%	13.8%	1
Phase 2	6	0%	21.0%	1
Phase 3	11	2%	59.0%	7
Total	**20**	**1%**	**13.8%**	**3**



Source: Global Data, MIT

- Approximately 55% of therapies in the NYC drug development pipeline were in the Phase III stage at year-end 2023.
- Artificial intelligence (AI) methods are now critical in the R&D process and throughout the drug development pipeline. Implementation of AI technology can accelerate productivity in drug discovery, clinical trials, testing of existing drugs for new uses and aggregation of data at scale.
- Established biopharma companies are increasingly investing in AI-focused start-ups, and this field will continue to be a primary driver of the life sciences innovation engine.

New Jersey company formation timeline suggests sustained local manufacturing demand



Source: Lightcast

Philadelphia company formation timeline suggests sustained local manufacturing demand



Source: Lightcast

NYC company formation timeline suggests sustained local manufacturing demand



Source: Lightcast

Section 2

Cluster map and stats

Incubators, multi-tenant R&D campuses & manufacturing clusters



% Available is for laboratory space / excludes office or flex available

Multi-tenant R&D campuses | Lab ready buildings | Coming to market

	Market Size (SF)	Direct Available SF	Direct Vacancy Rate
Central NJ	6,666,425	830,394	12.5%
Northern NJ	1,894,125	450,368	23.8%
Leased inventory			
Note - 139 FDA licensed Biopharma MFG facilities, most in US (Primarily owned)			

EXISTING INCUBATORS

No.	Address	Availability/Notes
1	NJ Bioscience Center 685 Route 1, North Brunswick	• Small incubator availabilities only • Accelerator is fully leased
2	Princeton BioLabs 303 College Road East, Princeton	• Open office & general lab availabilities only
3	Institute of Life Science & Entrepreneurship 1085 Morris Avenue, Union	• 15,000 SF fully occupied
4	Incubation & Collaboration Center Off of Route 78, Summit	• 16,000 SF office and lab facility within BMS Summit West campus • Rigorous application process required • Legacy Celgene initiative



Your Next Big Idea Starts Here

Discover the ultimate destination for scientific discovery at NEST. Our existing Class-A research & development facilities feature a turn-key vivarium and multiple customizable development opportunities, offering your organization solutions for today and limitless possibilities for tomorrow.

CONCEPTUAL RENDERING

Section 3

Northeast Life Sciences Corridor

Northeast life science labor and incentives

R&D and Manufacturing functions

The scale and composition of Research & Development and Life Science related Manufacturing positions across multiple markets show that there is an abundance of talent and a relatively comparable sized labor pool from Maryland north to Manhattan. Boston/Cambridge is leading the way and Raleigh/Durham has experienced tremendous growth in recent years. All markets provide the general talent depth and experience levels to scale which allows for them to be considered and contrasted on other metrics.

Strongest East Coast Life Science Markets





	Cost*		Pop. (000s)	
Location	Average Salary	Index (US=100)	w/ Bachelor's	Graduate+
Boston/ Cambridge	$108,094	114	793	688
Maryland/DC	$109,399	116	907	849
New Jersey	$105,824	112	1,087	727
New York	$108,891	115	1,925	1,460
Philadelphia	$101,229	107	920	632
Raleigh-Durham	$98,634	104	385	258

** Includes Bioprocess Engineers, Bioprocess Scientists, Biochemical Engineers, and Bioinformatics Engineers*

Rutgers Health :

The health care education,

research, and clinical division at

Rutgers University

Nov 19, 2024

Najwa Borkadi, Ph.D.
Executive Director, Research Business Development

Rutgers Health

Empowering Health for All

Rutgers Health is a nationally-recognized leader in research and innovation, driving groundbreaking discoveries, cutting-edge clinical care, and economic growth. Through basic, clinical, population, and translational research, Rutgers Health researchers are transforming education, improving lives, and advancing knowledge across the life sciences, physical sciences, and social sciences.



President Barack Obama: Rutgers "… what might just be America's most diverse student body…" *Commencement Address, May 2016*

Newark

Arts & Sciences | Business | Law

Newark & New Brunswick

Medical School | Pharmacy | Nursing | Public Health | Health Professions | Hospital system

New Brunswick

Art & Sciences | Engineering | Public Policy | Social Work | Labor Relations | Business | Graduate Education | Communication & Information | Environmental & Biological Sciences

Camden

Arts & Sciences | Business | Law | Nursing

Rutgers By the numbers



RUTGERS Let's be healthy together.

RWJBarnabas HEALTH

RWJBarnabas Health and Rutgers locations offer a vast network of clinical providers in 17 of New Jersey's 21 counties.*



* Dark areas of the map represent the combined geographic coverage of RWJBarnabas Health and Rutgers which have signed in 2021 Letter of Partnership

RUTGERS HEALTH AT A GLANCE

Top 20 Best Graduate Schools

Rutgers Health is home to top-ranked masters and doctorate of nursing programs, according to U.S. News & World Report.

450+ Clinical Trials

Rutgers Health supports approximately 450 or more clinical trials at any given time, advancing medical research and innovation.

2.3M Annual Patient Visits

Rutgers Health serves millions of patients each year, providing high-quality, patient-centered care across New Jersey.

36 AAAS Faculty Fellow

Rutgers Health is home to 36 faculty members who are fellows of the American Association for the Advancement of Science, a prestigious honor.

Rutgers Health is an education, research, and health care powerhouse, driving excellence in medical education, groundbreaking research, and exceptional patient care across New Jersey and beyond.

Rutgers Health Entities

Schools

- Ernest Mario School of Pharmacy
- New Jersey Medical School
- Robert Wood Johnson Medical School
- Rutgers School of Dental Medicine
- School of Graduate Studies (joint with RU – New Brunswick)
- School of Health Professions
- School of Nursing
- School of Public Health

Centers/Institutes

- Brain Health Institute
- Center for Advanced Biotechnology and Medicin
- Environmental and Occupational Health Sciences Institute
- Institute for Health, Health Care Policy and Aging Research
- Institute for Infectious and Inflammatory Diseases
- Rutgers Cancer Institute of NJ
- Rutgers Institute for Translational Medicine & Science

Behavioral Health Care Unit

- University Behavioral Health Care

Rutgers Health

Rutgers Health
Rutgers Health Group

Established in 2016

RESEARCH ACROSS RUTGERS HEALTH SCHOOLS

Ernest Mario School of Pharmacy

Five academic departments are actively engaged in high-impact research programs, in areas that include drug discovery and delivery, experimental therapeutics, and pharmacy practice.

New Jersey Medical School

Researchers study brain injury, immunology and infectious diseases, stem cells and regeneration, public health, and neurology. The renowned Global Tuberculosis Institute is also housed at the school.

Robert Wood Johnson Medical School

Home to major research institutes that focus on a range of topics, from cardiovascular medicine to women's health.

Rutgers School of Dental Medicine

Research extending from the prevention of cavities and periodontal disease to potential therapies for cancer and drug-resistance illness.

School of Public Health

Home to a number of research centers including the Center for Public Health Workforce Development, Center for South Asian Quantitative Health & Education, and New Jersey's Center on Gun Violence Research, among the first such centers in the country.

TRANSLATING DISCOVERIES INTO HEALTH

Leveraging Expertise

Rutgers Health brings together world-class researchers, clinicians, and innovators to tackle complex health challenges and translate groundbreaking discoveries into practical solutions.

Accelerating Innovation

With state-of-the-art facilities, robust research infrastructure, and a collaborative culture, Rutgers Health drives the development of novel therapies, devices, and technologies that improve patient outcomes.

Fostering Partnerships

Rutgers Health forges strategic alliances with industry leaders, government agencies, and patient advocacy groups to ensure that scientific breakthroughs have meaningful impact on the health and well-being of individuals and communities.

Impacting Lives

From pioneering new treatments for chronic diseas to developing cutting-edge digital health tools, Rutgers Health is dedicated to transforming biomedical research into real-world solutions that enhance the quality of life for people across New Jersey and beyond.

ALIGNING RH INTEREST WITH INDUSTRY FOCUS

COMPANY INTEREST

Expertise

Scientific & clinical know-how

IP

Intellectual property (IP) and IP-enabling research

Clinical

Patients & disease expertise
Data & Specimens

Talent

Workforce development

RBHS INTEREST

Expertise

- Sponsored research (single projects)
- Master agreements (multi-projects)
- Consortia. - Co-development

IP

- Licensing agreements
- Research collaborations

Clinical

- Clinical Trials
- Clinical Research

Talent

- Consulting
- Fellows, post-docs, graduate students, faculty

The RBHS Roadmap for a research Agreement



Rutgers checkpoints

The Business Research Development team assists the PIs with these checkpoints to make the collaboration move at Business Speed

Rutgers Internal process

The different units at the Office for Research facilitate every step the Rutgers' research administration process.

Rutgers Cancer Institute Overview

Christopher Molloy, PhD, RPh
Rutgers Cancer Institute
November 2024

RWJBarnabas HEALTH

RUTGERS HEALTH
Rutgers Cancer Institute

Associate Director for BioPharma Alliances (RCI)

Christopher J. Molloy, PhD, RPh

- University Professor
- Distinguished Professor of Pharmacology & Toxicology Rutgers Ernest Mario School of Pharmacy
- Drug discovery team leader at BMS, biotech, and J&J
- 2007 – Dean, Rutgers Ernest Mario School of Pharmacy
- 2011 – Interim Provost managing Rutgers/UMDNJ integration
- 2013 - Post integration, Senior VP for Research and Economic Development
- 2018 - Chancellor, Rutgers University – New Brunswick

Mission

- Identify and facilitate industry relationships to increase clinical and research competitiveness
- Increase external research funding through corporate and other strategic collaborations
- Represent CINJ with specific internal and external audiences.
- Connect clinicians and researchers with Rutgers resources supporting technology transfer, patents, licensing, and business development.

Historic Timeline

NCI P20 Planning Grant
UMDNJ: MA Gallo

1992

Founding Director
UMDNJ: WN Hait

1993

PRINCETON UNIVERSITY

Consortium with
Princeton University

1994

75,000 sq. ft.
Facility

1996

NIH NATIONAL CANCER INSTITUTE

NCI Designation
Conferred

1997

NCI Designated Comprehensive Cancer Center

Comprehensive Cancer
Center status conferred

2002

125,000 sq. ft.
Facility Expansion

2004

Director
RS DiPaola

2008

RUTGERS

UMDNJ integrates
into Rutgers University
Cancer Center is an
Independent Institute

2013

Director
SK Libutti

2017

RUTGERS Cancer Institute of New Jersey
RUTGERS HEALTH
NCI Comprehensive Cancer Center

CGSG Renewed -
Year 20

2019

RWJBarnabas HEALTH

Integrated Practice
Agreement with RWJBH

2021

RUTGERS HEALTH Rutgers Cancer Institute
NCI Designated Comprehensive Cancer Center

CGSG Renewed -
Year 25

2024

Jack and Sheryl Morris
Cancer Center

2025

The State of New Jersey

9.3 million people within 1,263 sq. mi.

1st	6th	7th
in population density – 9.3 M people within 1,263 mi^2	most ethnically diverse state	in cancer incidence (2021)

Racial, ethnic and socioeconomic disparities

in cancer incidence, mortality and access to care

23%	10%	10-23%
of New Jersey residents are foreign born	of households fall below the national poverty level	higher cancer rates in Rutgers Cancer Institute high-priority areas

RWJBarnabas HEALTH

RUTGERS HEALTH Rutgers Cancer Institute

Age-Adjusted Cancer Incidence Rates

(Per 100 K, all cancer sites combined, 2021)



Catchment Area Priority Cancers and Risk Factors

Priority Cancers



Risk Factors (and Icon Key):

- Obesity/Metabolic Dysregulation
- HPV Infection
- Tobacco Use
- Environmental Exposures
- Hereditary Cancers
- Access Barriers
- Social Determinants of Health

RWJBarnabas HEALTH

RUTGERS HEALTH
Rutgers Cancer Institute

ScreenNJ Partners: Impact and Reach

July 2017 – June 2018

Laying the Groundwork



- 20 clinical & outreach partners
- 3 counties

Community partnerships

Awareness, prevention, screening & timely diagnosis/treatment

Greater statewide reach

July 2018 – Aug 2024

Statewide Expansion

- 292 clinical & outreach partners
- 522 sites
- All 21 counties



34,500+
Tobacco cessation counseling

98,000+
Patients navigated to screening

7,700+
Cancers and premalignant lesions detected

NJ Health New Jersey Department of Health | American Cancer Society | NJCEED | NJPCA New Jersey Primary Care Association | *NJ Regional Health Coalitions* | American Lung Association. | Rutgers School of Public Health | Rutgers Cancer Institute

CCSG Research Programs

Cancer Metabolism and Immunology



Genomic Instability and Cancer Genetics



Cancer Pharmacology

Clinical Investigations and Precision Therapeutics

Cancer Prevention and Control

RWJBarnabas HEALTH

RUTGERS HEALTH
Rutgers Cancer Institute

Rutgers Cancer Institute System

- 12 adult hospitals across NJ
- One Oncology Service Line
- Clinical trials open and actively accruing at 10 (RWJBH) and 2 (CINJ) sites
- All System Sites with open trials
- New Affiliates



Unified Clinical Trials Infrastructure

Our Vision (2018)

Accomplished 2018-2022

- **One** IRB
- **One** Contract/Budget process
- **One** EMR
- **One** CTMS
- **One** Pharmacy
- **One** Clinical Trials and Quality Assurance Office

Unified Clinical Trials Infrastructure

Our Concept:

Centralized
- Operations
- Data Management

Sites Contribute
- Ideas
- Protocols
- Principal Investigators
- Patient Enrollment
  Data Management

Interventional Treatment Enrollment (2019-2024)



RWJBarnabas HEALTH

RUTGERS HEALTH
Rutgers Cancer Institute

Clinical Trial Portfolio 2023

Treatment protocols	232
Interventional non-treatment	+ 24
Total Interventional Trials	25 6



Accrual of Minorities to Therapeutic Trials

Minority Enrollment to Interventional Therapeutic Trials
(2019-2023)



18 %

Clinical Trial Collaborations

BIG CANCER RESEARCH CONSORTIUM

Teaming up to fight cancer

22
Trials Activated

11
Rutgers Cancer Institute PIs (CIPT)

RWJBarnabas HEALTH

RUTGERS HEALTH
Rutgers Cancer Institute

Growth: Facilities and Clinical Services

New Brunswick Today

- Primary clinical and research facility (225,000 sq. ft.)
- Dedicated oncology space (36,000 sq. ft.)
- Leased Administration (40,000 sq. ft.)
- RWJUH Oncology Hospital

New Brunswick Planned

- 520,000 sq. ft. Inpatient/Outpatient Morris Cancer Center
- Completion 2024

Total Cancer Program Allocated Space (sq. ft.)



Research (Wet and dry laboratories, OHRS)

Clinical (Patient care, Practice Management, clinical faculty/staff offices and workstations, patient/ physician/nursing education)

Administrative (Administration, Finance, IT, COE, DEI, CRTEC)

Jack and Sheryl Morris Cancer Center

Outpatient Care

- 86 infusion bays
- 84 exam rooms
- 4 linear accelerators; other advanced radiation oncology
- Diagnostic radiology equipment (e.g., CT, MRI, PET, mammography)
- Core and clinical laboratories
- Pharmacy
- Outpatient Urgent Care

Inpatient Care

- 96 private room inpatient beds on three floors
- Dedicated floor for nine surgical and two procedure rooms
- Central sterile processing area
- Inpatient support spaces

Research

- 10 wet lab facilities and equipment to support ten research teams
- Office of Human Research Services
- Faculty offices

Thank You

Q&A Segment

RUTGERS
Cancer Institute
of New Jersey
RUTGERS HEALTH

RUTGERS

PRINCETON UNIVERSITY

RWJBarnabas HEALTH

Future Plans

1. Continue to invest in Cancer Immunology and Metabolism, through faculty recruitment and infrastructure development
2. Complete construction of and operationalize Jack and Sheryl Morris Cancer Center and new RWJBH oncology outpatient facilities in Livingston and Monmouth
3. Continue to increase multi-project grants, leveraging opportunities with University O , a U01 within the CPC Program, and collaborations with other NCI-designees
4. Continue to expand impact on the catchment area made possible through the launch of the new mobile unit and doubling of the ScreenNJ budget
5. Reduce the cancer burden, improve outcomes and address health equity through multidisciplinary research, outreach and community
6. Implement diversity plan to increase and enhance representation among members and leadership

Develop 2026 – 2030 Strategic Plan

RWJBarnabas HEALTH

RUTGERS HEALTH Rutgers Cancer Institute

New Jersey Alliance for Clinical and Translational Science (NJ ACTS)

Reynold A. Panettieri. Jr., M.D.
Vice Chancellor for Translational Medicine and Science

http://njacts.rbhs.rutgers.edu

Translational Research Is a Continuum



Academic assets for commercialization include new drugs, devices, diagnostics and software

New Jersey Alliance for Clinical & Translational Science



Transformative Accomplishments over 5 years

- Established and implemented a Clinical Research Data Warehouse (CRDW).
- Built a robust Pilot Program fostering alliance partner collaboration.
- Supported a microcredentialing and badging program across Cores.
- Fostered a network of networks for community engaged research.
- Served as the Biomarker Core for the national pediatric Recover Program.
- Created a unique Clinical Trials Office to facilitate and catalyze clinical trials execution.
- Support the career development of 12 KL2 Scholars, 19 Predoc and 13 Postdoc trainees.
- Successfully competed for the continuation of NJ ACTS for 7 years.


Linked Databases
(EHR, Omics, CMS, Medicare, etc.)
Discovery
Practice
Policy
Dissemination Implementation Science
Translational Research
Processes
Translational Science

Clinical Trials Office

- Mandate through CTSA to improve the efficiency & quality of the clinical trials conducted here; the goal is also to increase the volume of trials
- Scope: Rutgers Health non-oncology clinical trials and non-clinical trials with billable clinical procedures

Rutgers Institute for Translational Medicine & Science

Workflow today

team submits documents through OnCore ePRMS (before IRB &

CTO Feasibility Navigator reviews submission, conducts Intake Assessment

used in OnCore to delegate:

1. Contract negotiation
2. Budget Negotiation
3. Medicare Coverage Analysis
4. Study Build in OnCore
5. Partner Hospital

*UH-Newark: CTO handles partner hospital submission responsible

RWJBH: Study teams are

Translational Research Home- RH Building

RUTGERS HEALTH

The Development

- Preliminary site plan and building sizes have been revised
- RH Building (RWJMS, Translational Research, Chancellor Office) is largest occupant in first building



- Phase 1 – RH space, Lab and Office, Innovation Hub/Coworking, RU-NB space
- Phase 2 – Nokia Bell Labs
- Phase 3 – TBD

Questions?

RUTGERS HEALTH

RUTGERS HEALTH

RWJBarnabas HEALTH

Center for Innovation

Advancing Health through Digital Technologies and Strategic Partnerships

i^3 - Innovation Model for Healthcare



Drive transformation and innovation in cardiovascular education, research, and clinical care

Slide courtesy: @Bhavnani

Use of Analogies : Data-driven Knowledge Discovery





Digital transformation of any domain will not be technology, but mirroring of AI and IA – promoting creativity and innovation.

CREATING A CULTURE OF INNOVATION

Sep 14th, 2022

CREATING SOLUTIONS WITH TECHNOLOGY

A NEW CENTER FOR INNOVATION BUILDS PATHWAYS TO MEDICAL BREAKTHROUGHS.

“ Bridging the Gap ”



Center for Innovation

IT Infrastructure, Software & Computational Resources

- Computer Vision
- Signal Processing
- NLP
- Deep Learning

AI/ML

- EHR/EMR
- Time Series Data
- Longitudinal Data
- Continuous Signals

BIG DATA

- Robotics
- Wearables
- POC Devices
- Remote Monitoring Devices

mHealth

- Genomics
- Transcriptomics
- Metabolomics
- Radiomics

Precision Medicine@Health

Leverage AI/ML techniques for clinical decision support, risk scoring, and early detection of diseases and to improve the quality of care at large.

Center for Innovation: Partnerships

HeartSciences

Butterfly™

biofourmis



AdEchoTech
Imaginons ensemble l'image de demain
Let us picture the future

Us2.AI

Center for innovation: New Breakthroughs

Point of Care Ultrasound Devices (LEVEL-2 SCREENING)



Ultrasonic Texture Features



IDEATE

AMERICAN COLLEGE of CARDIOLOGY



AI



Predicts severe obstructive and high-risk CAD better than

Distinguishes between healthy & infarcted

Opens new opportunities for advancing myocardial tissue characterization using basic echocardiography imaging, which was **previously only possible through advanced imaging**

Center for innovation: New Breakthroughs



Digital Twin
Virtual representation of a patient.
Seamlessly integrates their clinical data collected over time.









Cardiologists were unable to discriminate between **real** and **synthetic TDIs**, demonstrating the realism of the GAN-based waveforms.

Generative AI to synthetically generate **Digital Twins**

Center for innovation: New Breakthroughs

Technology that goes beyond just sound & music to "Hearing the Heart"

ECG/EKG POC Devices/Wearables (LEVEL-1 SCREENING)

Clinically validated & shows 99% correlation with



Invasive Blood Pressure monitoring using



Center for innovation: Ideate to Implement

Patient Site : CRC

Expert Site

AdEchoTech
Imaginons ensemble l'image de demain
Let us picture the future

Installation of a Clinical Robotic Tele-Ultrasound System.

First in the US!

Future : Command Centers & Care Pods



Center for innovation: Ideate to Implement

Partnership with Us2.ai to Bring an AI-assisted Echocardiography Integration to Cardiovascular Workflow

WORKFLOW WITH MACHINE

More time for "humane" work

Manual
~25 – 45 mins

~2 - 5 mir
Automated
AI



Easy. Zero clicks to a full report with disease detection

Fast. 2D, Doppler & Strain, all auto-measured in real time

Accurate. No variability, interchangeable with experts, worldwide regulatory approvals

Everywhere. Connect to echo CARTs, CVIS, PACS, on-prem, mobile or cloud

Augmented Physicians: Fight burn out & promote standardization of care across the Health System

US2.AI

Innovation & Beyond

Community based Cardiac Screening Events

Leverage modern innovations to advance cardiac health, enhance preventive care, and foster community well-being.



Image Source: [Precision Medicine at UCSF]

Ongoing Efforts

- Rutgers Clinical Data Warehouse
- RWJUH Data Lake

‘Innovation Genome’ : Precise & Personalized Medicine



ACC RoadMap for Innovation. JACC 2017

Innovations in Cardiovascular Therapies

Cardiac Surgery 1953

Cardiac Transplant 1967

Minimally Invasive Cardiac Surgery 1990s

2020

3D-printed tissue Gene Therapies

Cardiac Cath 1927

Drugs CCU 1962

Invasive Cardiology 1977

Structural Heart Interventions 2002

Nanoparticles

2040

Nanorobotics



A Paradigm Shift in How Healthcare is Delivered

Thank You!

yanamala.naveena@rutgers.edu

@YanamalaNaveena

Embracing AI as a partner in healthcare enhances patient care, boosts diagnostic accuracy, and fosters medical innovation…

RUTGERS UNIVERSITY
Office for Research

Deborah Perez Fernandez, Ph.D., M.B.A.
Executive Director,
Technology Transfer

Technology Commercialization

Why Technology Transfer

Bayh-Dole Act of 1980
Universities and nonprofits are allowed to commercialize inventions resulting from federal funding

IMPACT society with innovations

RAISE visibility of university research

RECRUIT, RETAIN, AND REWARD faculty, post-docs and students

STIMULATE economic development

CREATE new collaborative funding opportunities

RECEIVE credit and recognition for contributions

How It Works

The Technology Transfer and New Ventures Teams Are Here to Assist Throughout This Process

https://research.rutgers.edu/faculty-staff/inventions-commercialization/submitting-invention-disclosures

Technology Transfer and New Ventures = Rutgers Innovation

Technology Transfer	New Ventures
Assess Notice of Invention (NOI)	Rutgers Business and Startup Mentoring/Consulting
Determine IP strategy	Provide access to education (e.g. NSF I-Corps, Activate)
File for patents/trademarks/certificates	Review pitch decks before sending to investors/funders
Market innovation and find suitable partners	Introduction to service providers (e.g. lawyers)
Negotiate and execute licenses and other agreements	Identify and approach business founders
Maintain an accurate database of all innovations	Identify and access funding opportunities
Ensure compliance including with Bayh-Dole Act	Events with featured speakers
Ensure contract compliance	Assisting with business development
Innovation Recognition/Showcase Awards and Events	Manage the TechAdvance/HealthAdvance Funding

HealthAdvance & TechAdvance Create Follow-On Funding

TechAdvance Awards



TechAdvance Numbers Since 2017	
Funding Rate	~80%
Total Funding Disbursed	> $ 4.9 M
Follow-on Funding	**~ $17.4 M**

HealthAdvance Awards



HealthAdvance Numbers Since 2020	
Funding Rate	~53%
Total Funding Disbursed	> $ 3.6 M
Follow-on Funding	**~ $ 11.1 M**

* Includes 1 NIH RADx-Rad Award

Technology Transfer Trainee Program



Interns, Trainees, and Fellows Learn:

- How to protect and commercialize the results of scientific research.
- How to evaluate an Invention Disclosure, prepare Non-Confidential Summaries, and identify and reach out to prospective licensees.
- Business terms of various agreements that govern Technology Transfer in an academic university.

Fiscal Year 2024 Outcomes



Successes

Estée Lauder - Moringa anti-inflammatory, anti-aging skin cream

Cytotracker Leuketometer - Handheld white blood cell tracker

Axion – 100 % recycled plastic railroad ties

Medtronic – absorbable antibacterial envelope for implantable devices

Disease resistant basil plants

FY24 National Academy of Inventors Fellows

Fred Kramer
Patrick Sinko

FY24 Edison Patent Award Winners

Charles Dismukes
Martha Greenblatt
Andres Laursen
Karin Calvinho
Abraham Pinter
Alok Choudhary

Questions

innovate@research.rutgers.edu

Discussion

Thank you: Najwa Borkadi